Concordant care in sentinel lymph node omission following Choosing Wisely® recommendations at a comprehensive cancer center.
Am J Surg
; 227: 183-188, 2024 Jan.
Article
em En
| MEDLINE
| ID: mdl-37821293
ABSTRACT
BACKGROUND:
In 2016, the SSO and ABIM released a Choosing Wisely® guideline stating SLNB can be safely omitted in women ≥70 with HR â+ âHER-invasive breast cancer. No study evaluating concordance of care with this guideline has been performed within a comprehensive cancer center.METHODS:
From 2005 to 2020, there were 382 patients with cT1-2N0 invasive carcinoma ER+/PR+ and HER2-identified as having undergone SLNB. These patients were then separated into two groups; those in the pre-guideline concordance cohort (2005-2015) and those in the post-guideline concordance (2016-2020) cohort. Axillary management concordance was trended over time.RESULTS:
382 patients from 2005 to 2020 with HR â+ âHER- IBC were identified. No difference was seen in SLNB pre-versus post-guidelines (p â= â0.35). Increased concordance was noted as age increased (p â= â0.0068) and adjuvant radiation therapy exclusion (p â< â0.0001) post-guideline release. Concordance improved over the years post-guideline release (R2 â= â0.45).CONCLUSIONS:
Surgical guideline adoption occurs over time but may also be affected by outside decisions and factors. Further study into patterns of guideline adoption may facilitate improving adherence to guidelines.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Linfonodo Sentinela
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
Am J Surg
Ano de publicação:
2024
Tipo de documento:
Article